首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions- case example Amphotericin B
【24h】

Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions- case example Amphotericin B

机译:在健康和低碱性模拟肠外肠外肠外肠外肠外肠外肠外肠外肠外肠外肠外肠外肠外溶解的调查和模拟 - 例实施例两性霉素B.

获取原文
获取原文并翻译 | 示例
       

摘要

Guidance on dissolution testing for parenteral formulations is limited and not often related in vivo performance. Critically ill patients represent a target cohort, frequently hypoalbuminaemic, to whom certain parenteral formulations are administered. Amphotericin B (AmB) is a poorly soluble, highly protein-bound drug, available as lipid-based formulations and used in critical illness. The aim of this study was to develop media representing hypoalbuminaemic and healthy plasma, and to understand and simulate the dissolution profile of AmB in biorelevant media. Dissolution media were prepared with bovine serum albumin (BSA) in Krebs-Ringer buffer, and tested in a flow through cell apparatus and a bottle/stirrer setup. Drug activity was tested against Candida albicans. BSA concentration was positively associated with solubility, degradation rate and maximum amount dissolved and negatively associated with dissolution rate constant and antifungal activity. In the bottle/stirrer setup, a biexponential model successfully described simultaneous dissolution and degradation and increased in agitation reduced the discriminatory ability of the test. The hydrodynamics provided by the flow-through cell apparatus was not adequate to dissolve the drug. Establishing discriminating test methods with albumin present in the dissolution media, representing the target population, supports future development of biorelevant and clinically relevant tests for parenteral formulations.
机译:对肠胃外制剂的溶出试验的指导是有限的,并且不与体内性能相关。危重患者代表目标队列,经常进行低恶碱液,给予某些肠胃外制剂。两性统成蛋白B(AMB)是一种可溶的高度蛋白质结合药物,可作为脂质的制剂可用并用于危重疾病。本研究的目的是开发代表低碱性和健康等离子体的培养基,并理解和模拟Biorelevant介质中AMB的溶出轮廓。用krebs-ringer缓冲液中用牛血清白蛋白(BSA)制备溶ol培养基,并在流过电池装置和瓶/搅拌器设置中测试。药物活性对念珠菌白醛糖醛糖。 BSA浓度与溶解性,降解速率和溶解的最大量呈正相关,与溶解速率恒定和抗真菌活性负相关。在瓶子/搅拌器设置中,Biexponential模型成功地描述了同时溶解和降解,搅拌的增加降低了测试的歧视能力。流通电池设备提供的流体动力学不适用于溶解药物。在溶解培养基中建立鉴别试验方法,代表靶人群,支持对肠外配方进行生物的未来发展和临床相关的测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号